migraine Archives - Journal for Clinical Studies

Current Edition

Regional News

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Novartis and Amgen have spent years arm wrestling one another over their development and commercialization deal on migraine prevention drug Aimovig. Now, the parties ...

2 February 2022 Regional News Amgen | drug

Continue Reading →

Regional News

Amgen’s Otezla, Repatha and biosimilars put on notice, with challenging years ahead

Some of Amgen’s key businesses are drawing concerns as competition looms. Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry watche...

24 November 2021 Regional News Aimovig | Amgen Repatha

Continue Reading →

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Decentralised Clinical Trials in The EU

RWS – eBook

It’s All About Stem Cells

Covid-19

Current Edition

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Amgen’s Otezla, Repatha and biosimilars put on notice, with challenging years ahead

Journal for Clinical Studies